426 related articles for article (PubMed ID: 10232610)
41. The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal.
Pause A; Lee S; Lonergan KM; Klausner RD
Proc Natl Acad Sci U S A; 1998 Feb; 95(3):993-8. PubMed ID: 9448273
[TBL] [Abstract][Full Text] [Related]
42. The von Hippel-Lindau gene product inhibits vascular permeability factor/vascular endothelial growth factor expression in renal cell carcinoma by blocking protein kinase C pathways.
Pal S; Claffey KP; Dvorak HF; Mukhopadhyay D
J Biol Chem; 1997 Oct; 272(44):27509-12. PubMed ID: 9346879
[TBL] [Abstract][Full Text] [Related]
43. Von Hippel-Lindau disease and sporadic renal cell carcinoma.
Zbar B
Cancer Surv; 1995; 25():219-32. PubMed ID: 8718521
[TBL] [Abstract][Full Text] [Related]
44. Regulation of E2F1 by the von Hippel-Lindau tumour suppressor protein predicts survival in renal cell cancer patients.
Mans DA; Vermaat JS; Weijts BG; van Rooijen E; van Reeuwijk J; Boldt K; Daenen LG; van der Groep P; Rowland BD; Jans JJ; Roepman R; Voest EE; van Diest PJ; Verhaar MC; de Bruin A; Giles RH
J Pathol; 2013 Sep; 231(1):117-29. PubMed ID: 23744542
[TBL] [Abstract][Full Text] [Related]
45. Analysis of aberrant methylation of the VHL gene by transgenes, monochromosome transfer, and cell fusion.
Kuzmin I; Geil L; Ge H; Bengtsson U; Duh FM; Stanbridge EJ; Lerman MI
Oncogene; 1999 Oct; 18(41):5672-9. PubMed ID: 10523847
[TBL] [Abstract][Full Text] [Related]
46. VHL tumor suppressor regulates Cl-/HCO3- exchange and Na+/H+ exchange activities in renal carcinoma cells.
Karumanchi SA; Jiang L; Knebelmann B; Stuart-Tilley AK; Alper SL; Sukhatme VP
Physiol Genomics; 2001 Apr; 5(3):119-28. PubMed ID: 11285365
[TBL] [Abstract][Full Text] [Related]
47. Regulation of STRA13 by the von Hippel-Lindau tumor suppressor protein, hypoxia, and the UBC9/ubiquitin proteasome degradation pathway.
Ivanova AV; Ivanov SV; Danilkovitch-Miagkova A; Lerman MI
J Biol Chem; 2001 May; 276(18):15306-15. PubMed ID: 11278694
[TBL] [Abstract][Full Text] [Related]
48. Detection of circulating cancer cells with von hippel-lindau gene mutation in peripheral blood of patients with renal cell carcinoma.
Ashida S; Okuda H; Chikazawa M; Tanimura M; Sugita O; Yamamoto Y; Nakamura S; Moriyama M; Shuin T
Clin Cancer Res; 2000 Oct; 6(10):3817-22. PubMed ID: 11051223
[TBL] [Abstract][Full Text] [Related]
49. Genetic basis of cancer of the kidney: disease-specific approaches to therapy.
Linehan WM; Vasselli J; Srinivasan R; Walther MM; Merino M; Choyke P; Vocke C; Schmidt L; Isaacs JS; Glenn G; Toro J; Zbar B; Bottaro D; Neckers L
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6282S-9S. PubMed ID: 15448018
[TBL] [Abstract][Full Text] [Related]
50. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma.
Yao M; Yoshida M; Kishida T; Nakaigawa N; Baba M; Kobayashi K; Miura T; Moriyama M; Nagashima Y; Nakatani Y; Kubota Y; Kondo K
J Natl Cancer Inst; 2002 Oct; 94(20):1569-75. PubMed ID: 12381710
[TBL] [Abstract][Full Text] [Related]
51. Inactivation of von Hippel-Lindau gene induces constitutive phosphorylation of MET protein in clear cell renal carcinoma.
Nakaigawa N; Yao M; Baba M; Kato S; Kishida T; Hattori K; Nagashima Y; Kubota Y
Cancer Res; 2006 Apr; 66(7):3699-705. PubMed ID: 16585196
[TBL] [Abstract][Full Text] [Related]
52. [VHL, angiogenesis and renal carcinoma: the puzzle is complete].
Richard S
Ann Pathol; 2000 Mar; 20(2):107-9. PubMed ID: 10740003
[No Abstract] [Full Text] [Related]
53. TGF-beta1 acts as a tumor suppressor of human malignant keratinocytes independently of Smad 4 expression and ligand-induced G(1) arrest.
Paterson IC; Davies M; Stone A; Huntley S; Smith E; Pring M; Eveson JW; Robinson CM; Parkinson EK; Prime SS
Oncogene; 2002 Feb; 21(10):1616-24. PubMed ID: 11896591
[TBL] [Abstract][Full Text] [Related]
54. Tumor suppressor protein VHL is induced at high cell density and mediates contact inhibition of cell growth.
Baba M; Hirai S; Kawakami S; Kishida T; Sakai N; Kaneko S; Yao M; Shuin T; Kubota Y; Hosaka M; Ohno S
Oncogene; 2001 May; 20(22):2727-36. PubMed ID: 11420685
[TBL] [Abstract][Full Text] [Related]
55. [Development of human renal cell carcinoma (RCC)--the responsible genes for the development of hereditary and sporadic human RCCs].
Shuin T; Kamata M; Ashida S
Gan To Kagaku Ryoho; 2002 Oct; 29(10):1719-25. PubMed ID: 12402420
[TBL] [Abstract][Full Text] [Related]
56. pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development.
Stickle NH; Chung J; Klco JM; Hill RP; Kaelin WG; Ohh M
Mol Cell Biol; 2004 Apr; 24(8):3251-61. PubMed ID: 15060148
[TBL] [Abstract][Full Text] [Related]
57. JunB promotes cell invasion and angiogenesis in VHL-defective renal cell carcinoma.
Kanno T; Kamba T; Yamasaki T; Shibasaki N; Saito R; Terada N; Toda Y; Mikami Y; Inoue T; Kanematsu A; Nishiyama H; Ogawa O; Nakamura E
Oncogene; 2012 Jun; 31(25):3098-110. PubMed ID: 22020339
[TBL] [Abstract][Full Text] [Related]
58. Parathyroid hormone-related protein is an essential growth factor for human clear cell renal carcinoma and a target for the von Hippel-Lindau tumor suppressor gene.
Massfelder T; Lang H; Schordan E; Lindner V; Rothhut S; Welsch S; Simon-Assmann P; Barthelmebs M; Jacqmin D; Helwig JJ
Cancer Res; 2004 Jan; 64(1):180-8. PubMed ID: 14729622
[TBL] [Abstract][Full Text] [Related]
59. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein.
Kondo K; Klco J; Nakamura E; Lechpammer M; Kaelin WG
Cancer Cell; 2002 Apr; 1(3):237-46. PubMed ID: 12086860
[TBL] [Abstract][Full Text] [Related]
60. Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells.
Gunaratnam L; Morley M; Franovic A; de Paulsen N; Mekhail K; Parolin DA; Nakamura E; Lorimer IA; Lee S
J Biol Chem; 2003 Nov; 278(45):44966-74. PubMed ID: 12944410
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
